CRXT Clarus Therapeutics Bullish Reversal

CRXT Clarus Therapeutics had 3 green days after its sell-off to all time low.
This should signal a reversal pattern.
Clarus Therapeutics has the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions called JATENZO.

The fist target is the $1.1 private placement offering price and then the $2.10 resistance.
Few months ago they had another private placement at $4.96 per unit, so we can take that into consideration as well.
Needham & Company LLC has a Price Target of $8 for CRXT (that is the ultimate goal).

I think it can easily double from here.

Looking forward to read your opinion about it.